Nexvet Biopharma PLC Company Profile (NASDAQ:NVET)

About Nexvet Biopharma PLC

Nexvet Biopharma PLC logoNexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company's platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal's immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company's advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NVET
  • CUSIP:
Key Metrics:
  • Previous Close: $3.25
  • 50 Day Moving Average: $3.43
  • 200 Day Moving Average: $4.09
  • 52-Week Range: $11,752,000.00 - $2.61
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.91
  • P/E Growth: 0.00
  • Market Cap: $38.19M
  • Outstanding Shares: 11,752,000
  • Beta: 0.52
Profitability:
  • Return on Equity: -57.98%
  • Return on Assets: -50.99%
Debt:
  • Current Ratio: 7.69%
  • Quick Ratio: 7.69%
Additional Links:
Companies Related to Nexvet Biopharma PLC:

Analyst Ratings

Consensus Ratings for Nexvet Biopharma PLC (NASDAQ:NVET) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.00 (146.15% upside)

Analysts' Ratings History for Nexvet Biopharma PLC (NASDAQ:NVET)
Show:
DateFirmActionRatingPrice TargetDetails
8/16/2016Credit Suisse GroupReiterated RatingBuy$8.00View Rating Details
11/24/2015Cowen and CompanyReiterated RatingBuy$13.00View Rating Details
11/24/2015Piper Jaffray CompaniesReiterated RatingOverweight$17.00 -> $13.00View Rating Details
3/3/2015JMP SecuritiesInitiated CoverageOutperform$17.00View Rating Details
3/2/2015Bank of America CorpInitiated CoverageBuy$15.00View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for Nexvet Biopharma PLC (NASDAQ:NVET)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017        
5/12/2016Q3($0.44)($0.50)ViewN/AView Earnings Details
11/5/2015($0.51)($0.35)ViewN/AView Earnings Details
5/8/2015Q115($0.40)($0.36)ViewN/AView Earnings Details
3/16/2015($0.55)($2.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nexvet Biopharma PLC (NASDAQ:NVET)
Current Year EPS Consensus Estimate: $-1.80 EPS
Next Year EPS Consensus Estimate: $-1.70 EPS

Dividends

Dividend History for Nexvet Biopharma PLC (NASDAQ:NVET)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Nexvet Biopharma PLC (NASDAQ:NVET)
Insider Ownership Percentage: 37.00%
Institutional Ownership Percentage: 48.68%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/4/2016David GearingInsiderBuy11,113$3.33$37,006.29View SEC Filing  
3/2/2016Ashraf HannaDirectorBuy1,500$3.20$4,800.00View SEC Filing  
2/26/2016Farallon Capital Management LlInsiderBuy435,000$3.19$1,387,650.00View SEC Filing  
2/24/2016Cormac G KiltyDirectorBuy3,000$3.17$9,510.00View SEC Filing  
9/10/2015Farallon Capital Management LlInsiderBuy11,100$6.46$71,706.00View SEC Filing  
9/9/2015Cormac G KiltyDirectorBuy10,000$4.79$47,900.00View SEC Filing  
2/10/2015One Funds Management Ltd Atf AMajor ShareholderBuy100,000$10.00$1,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Nexvet Biopharma PLC (NASDAQ:NVET)
DateHeadline
us.rd.yahoo.com logoNexvet Reports Financial Results for Second Quarter of Fiscal Year 2017 (NASDAQ:NVET)
us.rd.yahoo.com - February 10 at 7:54 PM
biz.yahoo.com logoQ2 2017 Nexvet Biopharma plc Earnings Release - Time Not Supplied (NASDAQ:NVET)
biz.yahoo.com - February 10 at 7:54 PM
News IconTechnical Tracker: Watching Shares of Nexvet Biopharma Plc (NVET) - Sherwood Daily (NASDAQ:NVET)
sherwooddaily.com - January 17 at 7:19 PM
investornewswire.com logoNexvet Biopharma plc (NASDAQ:NVET) Strong Sell Recommendations At {RATING_CNT_STRONG_SELLS:378}} - Investor Newswire (NASDAQ:NVET)
www.investornewswire.com - January 16 at 7:57 AM
News IconWill The Needle Move For Nexvet Biopharma plc (NASDAQ:NVET) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:NVET)
wsbeacon.com - January 14 at 4:42 AM
News IconNexvet Biopharma Plc (NVET) Valuation According To Analysts - UK Market News (NASDAQ:NVET)
www.ukmarketnews.co.uk - January 5 at 10:37 PM
investornewswire.com logoNexvet Biopharma plc (NASDAQ:NVET) Strong Buy Recommendations At 1 - Investor Newswire (NASDAQ:NVET)
www.investornewswire.com - January 3 at 5:13 PM
investornewswire.com logoNexvet Biopharma plc (NASDAQ:NVET) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:NVET)
www.investornewswire.com - December 26 at 6:20 PM
investornewswire.com logoCan Shares Of Nexvet Biopharma plc (NASDAQ:NVET) Hit $8? - Investor Newswire (NASDAQ:NVET)
www.investornewswire.com - December 12 at 10:00 AM
finance.yahoo.com logoNexvet Announces Initiation of Pivotal Efficacy Study of Frunevetmab in Cats (NASDAQ:NVET)
finance.yahoo.com - December 12 at 10:00 AM
capitalcube.com logoNexvet Biopharma PLC :NVET-US: Earnings Analysis: Q1, 2017 By the Numbers : December 6, 2016 (NASDAQ:NVET)
www.capitalcube.com - December 6 at 6:39 PM
News IconChart Inspection on Shares of Nexvet Biopharma Plc (NVET) - StockTalk Daily (NASDAQ:NVET)
stocktalkdaily.com - December 4 at 9:39 AM
News IconTrading Scout: Watching Shares of Nexvet Biopharma Plc (NVET) - Yankee Analysts (NASDAQ:NVET)
yankeeanalysts.com - December 3 at 10:56 AM
News IconWatching the Charts on Nexvet Biopharma Plc (NVET) - Yankee Analysts (NASDAQ:NVET)
yankeeanalysts.com - November 30 at 11:46 AM
News IconNexvet Biopharma Plc (NVET) Under Analyst Spotlight - UK Market News (NASDAQ:NVET)
www.ukmarketnews.co.uk - November 24 at 9:47 AM
News IconChart Watch: Following Indicators on Shares of Nexvet Biopharma Plc (NVET) - MicroCap Wired (NASDAQ:NVET)
www.microcapwired.com - November 23 at 9:45 AM
News IconTechnical Investor Update on Shares of Nexvet Biopharma Plc (NVET) - MicroCap Wired (NASDAQ:NVET)
www.microcapwired.com - November 22 at 10:49 AM
investornewswire.com logoCan Shares Of Nexvet Biopharma plc (NASDAQ:NVET) Smash $8? - Investor Newswire (NASDAQ:NVET)
www.investornewswire.com - November 21 at 11:49 AM
News IconCheck on Average Directional Index for Nexvet Biopharma Plc (NVET) - MicroCap Wired (NASDAQ:NVET)
www.microcapwired.com - November 21 at 11:49 AM
News IconAnalysts Watch Nexvet Biopharma Plc (NVET) And Issue New Targets - NewsDen (NASDAQ:NVET)
newsden.net - November 18 at 6:07 PM
News IconTrading Chatter: CCI and ADX Watch for Nexvet Biopharma Plc (NVET) - MicroCap Wired (NASDAQ:NVET)
www.microcapwired.com - November 18 at 9:45 AM
biz.yahoo.com logoNEXVET BIOPHARMA PLC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission (NASDAQ:NVET)
biz.yahoo.com - November 18 at 9:45 AM
News IconBroker Review: Nexvet Biopharma Plc (NVET) - UK Market News (NASDAQ:NVET)
www.ukmarketnews.co.uk - November 16 at 10:14 AM
investornewswire.com logoCan Shares Of Nexvet Biopharma plc (NASDAQ:NVET) Get To $8? - Investor Newswire (NASDAQ:NVET)
www.investornewswire.com - November 14 at 10:39 AM
News IconNexvet Biopharma Plc (NVET) Updated Broker Ratings - NewsDen (NASDAQ:NVET)
newsden.net - November 14 at 10:39 AM
News IconTechnical Update on Shares of Nexvet Biopharma Plc (NVET) - Yankee Analysts (NASDAQ:NVET)
yankeeanalysts.com - November 12 at 9:07 AM
News IconTrading Sheet: Tracking Technicals for Nexvet Biopharma Plc (NVET) - Yankee Analysts (NASDAQ:NVET)
yankeeanalysts.com - November 11 at 9:15 AM
News IconInvestor Corner: Checking the Charts for Nexvet Biopharma Plc (NVET) - Yankee Analysts (NASDAQ:NVET)
yankeeanalysts.com - November 9 at 6:28 PM
News IconTechnical Trading: Focus on Shares of Nexvet Biopharma Plc (NVET) - Yankee Analysts (NASDAQ:NVET)
yankeeanalysts.com - November 9 at 9:02 AM
News IconADX Update on These Shares: Nexvet Biopharma Plc (NVET) - Yankee Analysts (NASDAQ:NVET)
yankeeanalysts.com - November 5 at 8:52 AM
News IconInvestor Probe: Watching Technicals for Nexvet Biopharma Plc (NVET) - Yankee Analysts (NASDAQ:NVET)
yankeeanalysts.com - November 4 at 6:02 PM
News IconChecking on CCI, MA, RSI and ADX for Nexvet Biopharma Plc (NVET) - Yankee Analysts (NASDAQ:NVET)
yankeeanalysts.com - November 3 at 10:34 AM
investornewswire.com logoNexvet Biopharma plc (NASDAQ:NVET) Buy Calls At 0 - Investor Newswire (NASDAQ:NVET)
www.investornewswire.com - October 31 at 1:07 PM
News IconCurrent Price Targets For Nexvet Biopharma Plc (NVET) - NewsDen (NASDAQ:NVET)
newsden.net - October 26 at 6:35 PM
finance.yahoo.com logoNexvet to Present at the 25th Annual Credit Suisse Healthcare Conference (NASDAQ:NVET)
finance.yahoo.com - October 19 at 11:35 AM
News IconAnalyst Coverage: Nexvet Biopharma Plc (NVET) - NewsDen (NASDAQ:NVET)
newsden.net - October 14 at 6:19 PM
News IconRecently Changed Price Targets On Nexvet Biopharma Plc (NVET) - NewsDen (NASDAQ:NVET)
newsden.net - October 9 at 5:51 PM
finance.yahoo.com logoNEXVET BIOPHARMA PLC Financials (NASDAQ:NVET)
finance.yahoo.com - September 7 at 6:39 PM
publicnow.com logoNexvet Biopharma Reports Full Year Fiscal 2016 Results (NASDAQ:NVET)
www.publicnow.com - September 2 at 11:21 AM
biz.yahoo.com logoNEXVET BIOPHARMA PLC Files SEC form 10-K, Annual Report (NASDAQ:NVET)
biz.yahoo.com - September 2 at 11:21 AM
biz.yahoo.com logoQ4 2016 Nexvet Biopharma plc Earnings Release - Time Not Supplied (NASDAQ:NVET)
biz.yahoo.com - September 2 at 11:21 AM
biz.yahoo.com logoNEXVET BIOPHARMA PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi (NASDAQ:NVET)
biz.yahoo.com - September 2 at 11:21 AM
investornewswire.com logoWill Nexvet Biopharma plc (NASDAQ:NVET) Hit $12 Price Target? - Investor Newswire (NASDAQ:NVET)
www.investornewswire.com - August 22 at 11:08 AM
investornewswire.com logoIs $12 Price Target Attainable For Nexvet Biopharma plc (NASDAQ:NVET)? - Investor Newswire (NASDAQ:NVET)
www.investornewswire.com - July 25 at 10:59 AM
finance.yahoo.com logoNexvet Announces Publication of Two Peer-Reviewed Journal Articles Profiling Frunevetmab (NV-02) and Presentation at the Veterinary Pain Short Course Conference (NASDAQ:NVET)
finance.yahoo.com - July 20 at 5:30 AM
investornewswire.com logoStrong Sell Calls For Nexvet Biopharma plc (NASDAQ:NVET) At 0 - Investor Newswire (NASDAQ:NVET)
www.investornewswire.com - July 19 at 6:39 PM
investornewswire.com logoIs $12 Within Reach For Nexvet Biopharma plc (NASDAQ:NVET)? - Investor Newswire (NASDAQ:NVET)
www.investornewswire.com - July 10 at 5:55 PM

Social

What is Nexvet Biopharma PLC's stock symbol?

Nexvet Biopharma PLC trades on the NASDAQ under the ticker symbol "NVET."

Where is Nexvet Biopharma PLC's stock going? Where will Nexvet Biopharma PLC's stock price be in 2017?

1 analysts have issued 12-month price targets for Nexvet Biopharma PLC's shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate Nexvet Biopharma PLC's stock price to reach $8.00 in the next year.

When will Nexvet Biopharma PLC announce their earnings?

Nexvet Biopharma PLC is scheduled to release their next quarterly earnings announcement on Wednesday, May, 10th 2017.

Who owns Nexvet Biopharma PLC stock?

Nexvet Biopharma PLC's stock is owned by a number of of retail and institutional investors. Top institutional investors include Broadfin Capital LLC (9.61%), Foresite Capital Management II LLC (7.63%), AustralianSuper Pty Ltd (5.93%) and Boxer Capital LLC (1.32%). Company insiders that own Nexvet Biopharma PLC stock include Ashraf Hanna, Cormac G Kilty, David Gearing and Farallon Capital Management Ll.

Who sold Nexvet Biopharma PLC stock? Who is selling Nexvet Biopharma PLC stock?

Nexvet Biopharma PLC's stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management II LLC.

Who bought Nexvet Biopharma PLC stock? Who is buying Nexvet Biopharma PLC stock?

Nexvet Biopharma PLC's stock was bought by a variety of institutional investors in the last quarter, including Broadfin Capital LLC. Company insiders that have bought Nexvet Biopharma PLC stock in the last two years include Ashraf Hanna, Cormac G Kilty, David Gearing and Farallon Capital Management Ll.

How do I buy Nexvet Biopharma PLC stock?

Shares of Nexvet Biopharma PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Nexvet Biopharma PLC stock cost?

One share of Nexvet Biopharma PLC stock can currently be purchased for approximately $3.25.

Nexvet Biopharma PLC (NASDAQ:NVET) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Nexvet Biopharma PLC (NASDAQ:NVET)

Earnings History Chart

Earnings by Quarter for Nexvet Biopharma PLC (NASDAQ:NVET)

Dividend History Chart

Dividend Payments by Quarter for Nexvet Biopharma PLC (NASDAQ:NVET)

Last Updated on 2/20/2017 by MarketBeat.com Staff